Trial Profile
Phase I Study of Bendamustine, Rituximab, Ibrutinib, and Venetoclax in Relapsed, Refractory Mantle Cell Lymphoma
Status:
Completed
Phase of Trial:
Phase 0
Latest Information Update: 31 Jan 2024
Price :
$35
*
At a glance
- Drugs Venetoclax (Primary) ; Bendamustine; Ibrutinib; Rituximab
- Indications Mantle-cell lymphoma
- Focus Adverse reactions
- 24 Jan 2024 Status changed from active, no longer recruiting to completed.
- 29 Jun 2023 Planned End Date changed from 20 Sep 2023 to 20 Sep 2024.
- 29 Jun 2023 Planned primary completion date changed from 20 Sep 2023 to 20 Sep 2024.